Symbols / VOR Stock $14.57 -2.67% Vor Biopharma Inc.
VOR (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteVor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Ratings
Current target
$14.57
Low
$18.00
High
$50.00
Mean
$37.88
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-18 | reit | HC Wainwright & Co. | Buy → Buy | $31 |
| 2026-05-14 | main | Wedbush | Neutral → Neutral | $18 |
| 2026-04-15 | main | HC Wainwright & Co. | Buy → Buy | $31 |
| 2026-03-31 | main | Wedbush | Neutral → Neutral | $15 |
| 2026-03-30 | init | Jefferies | — → Buy | $50 |
| 2026-03-19 | init | Wells Fargo | — → Overweight | $30 |
| 2026-01-09 | init | Citigroup | — → Buy | $50 |
| 2025-12-19 | main | JP Morgan | Overweight → Overweight | $40 |
| 2025-12-17 | init | TD Cowen | — → Buy | — |
| 2025-12-09 | init | JP Morgan | — → Overweight | $43 |
| 2025-11-14 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-10-29 | main | HC Wainwright & Co. | Buy → Buy | $55 |
| 2025-10-15 | up | Baird | Neutral → Outperform | $64 |
| 2025-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-06-30 | up | HC Wainwright & Co. | Neutral → Buy | $3 |
| 2025-06-27 | main | Baird | Neutral → Neutral | $1 |
| 2025-06-26 | reit | Wedbush | Neutral → Neutral | $0 |
| 2025-05-09 | down | JMP Securities | Market Outperform → Market Perform | $6 |
| 2025-05-09 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-03-21 | reit | Oppenheimer | Outperform → Outperform | $8 |
News
RSS: Latest VOR news- Biotech Vor Bio hands 61,050 options, 12,900 RSUs to new staff - Stock Titan Mon, 01 Jun 2026 21
- Vor Bio grants stock options and RSUs to 10 new hires as inducements under Nasdaq rules. - Pluang Mon, 01 Jun 2026 21
- VOR Stock Price, Quote & Chart | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill Fri, 29 May 2026 07
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times Mon, 01 Jun 2026 21
- $VOR stock is down 11% today. Here's what we see in our data. - Quiver Quantitative ue, 07 Apr 2026 07
- Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade - Zacks Investment Research hu, 07 May 2026 07
- Vor Biopharma: It's A Game Of Wait And See (NASDAQ:VOR) - Seeking Alpha Wed, 08 Apr 2026 07
- Autoimmune biotech Vor Bio to share update at 2026 Jefferies conference - Stock Titan hu, 28 May 2026 12
- Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock - Yahoo Finance Mon, 10 Nov 2025 08
- VOR News | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill Wed, 27 May 2026 07
- $VOR stock is up 13% today. Here's what we see in our data. | VOR Stock News - Quiver Quantitative ue, 16 Dec 2025 08
- Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed? - Yahoo Finance Fri, 12 Dec 2025 08
- Six new Vor Bio hires get stock awards priced at $13.85 - Stock Titan Mon, 04 May 2026 07
- $VOR stock is up 7% today. Here's what we see in our data. - Quiver Quantitative Fri, 27 Mar 2026 07
- Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect? - Yahoo Finance Mon, 20 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
371.64
+206.67%
|
121.19
-3.85%
|
126.04
+34.92%
|
93.42
|
| Research And Development |
|
321.53
+244.58%
|
93.31
-1.07%
|
94.31
+46.11%
|
64.55
|
| Selling General And Administration |
|
50.11
+79.77%
|
27.88
-12.12%
|
31.72
+9.88%
|
28.87
|
| General And Administrative Expense |
|
50.11
+79.77%
|
27.88
-12.12%
|
31.72
+9.88%
|
28.87
|
| Other Gand A |
|
50.11
+79.77%
|
27.88
-12.12%
|
31.72
+9.88%
|
28.87
|
| Total Expenses |
|
371.64
+206.67%
|
121.19
-3.85%
|
126.04
+34.92%
|
93.42
|
| Operating Income |
|
-371.64
-206.67%
|
-121.19
+3.85%
|
-126.04
-34.92%
|
-93.42
|
| Total Operating Income As Reported |
|
-371.64
-206.67%
|
-121.19
+3.85%
|
-126.04
-34.92%
|
-93.42
|
| EBITDA |
|
-368.75
-213.42%
|
-117.66
+3.99%
|
-122.54
-34.82%
|
-90.89
|
| Normalized EBITDA |
|
-34.40
+70.77%
|
-117.66
+3.99%
|
-122.54
-34.82%
|
-90.89
|
| Reconciled Depreciation |
|
2.89
-18.17%
|
3.53
+1.03%
|
3.49
+38.30%
|
2.52
|
| EBIT |
|
-371.64
-206.67%
|
-121.19
+3.85%
|
-126.04
-34.92%
|
-93.42
|
| Total Unusual Items |
|
-334.36
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
-334.36
|
—
|
—
|
—
|
| Net Income |
|
-695.98
-495.29%
|
-116.91
+0.81%
|
-117.86
-27.98%
|
-92.09
|
| Pretax Income |
|
-695.98
-495.29%
|
-116.91
+0.81%
|
-117.86
-27.98%
|
-92.09
|
| Net Non Operating Interest Income Expense |
|
5.87
+37.39%
|
4.27
-47.74%
|
8.17
+517.30%
|
1.32
|
| Net Interest Income |
|
5.87
+37.39%
|
4.27
-47.74%
|
8.17
+517.30%
|
1.32
|
| Interest Income Non Operating |
|
5.87
+37.39%
|
4.27
-47.74%
|
8.17
+517.30%
|
1.32
|
| Interest Income |
|
5.87
+37.39%
|
4.27
-47.74%
|
8.17
+517.30%
|
1.32
|
| Other Income Expense |
|
-330.21
|
—
|
—
|
—
|
| Other Non Operating Income Expenses |
|
4.15
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
-334.36
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-695.98
-495.29%
|
-116.91
+0.81%
|
-117.86
-27.98%
|
-92.09
|
| Net Income From Continuing Operation Net Minority Interest |
|
-695.98
-495.29%
|
-116.91
+0.81%
|
-117.86
-27.98%
|
-92.09
|
| Net Income From Continuing And Discontinued Operation |
|
-695.98
-495.29%
|
-116.91
+0.81%
|
-117.86
-27.98%
|
-92.09
|
| Net Income Continuous Operations |
|
-695.98
-495.29%
|
-116.91
+0.81%
|
-117.86
-27.98%
|
-92.09
|
| Normalized Income |
|
-361.62
-209.31%
|
-116.91
+0.81%
|
-117.86
-27.98%
|
-92.09
|
| Net Income Common Stockholders |
|
-695.98
-495.29%
|
-116.91
+0.81%
|
-117.86
-27.98%
|
-92.09
|
| Diluted EPS |
|
-70.50
-107.17%
|
-34.03
+2.77%
|
-35.00
+24.89%
|
-46.60
|
| Basic EPS |
|
-70.50
-107.17%
|
-34.03
+2.77%
|
-35.00
+24.89%
|
-46.60
|
| Basic Average Shares |
|
9.87
+187.35%
|
3.44
+2.26%
|
3.36
+69.89%
|
1.98
|
| Diluted Average Shares |
|
9.87
+187.35%
|
3.44
+2.26%
|
3.36
+69.89%
|
1.98
|
| Diluted NI Availto Com Stockholders |
|
-695.98
-495.29%
|
-116.91
+0.81%
|
-117.86
-27.98%
|
-92.09
|
| Preferred Stock Dividends |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2024-12-31 | 2021-12-31 |
|---|---|---|---|
| Total Assets |
|
142.89
|
—
|
| Current Assets |
|
96.51
|
—
|
| Cash Cash Equivalents And Short Term Investments |
|
91.93
|
—
|
| Cash And Cash Equivalents |
|
81.95
|
—
|
| Other Short Term Investments |
|
9.98
|
—
|
| Prepaid Assets |
|
4.20
|
—
|
| Other Current Assets |
|
0.38
|
—
|
| Total Non Current Assets |
|
46.38
|
—
|
| Net PPE |
|
41.59
|
—
|
| Gross PPE |
|
52.80
|
—
|
| Accumulated Depreciation |
|
-11.21
|
—
|
| Properties |
|
—
|
0.00
|
| Machinery Furniture Equipment |
|
1.05
|
—
|
| Construction In Progress |
|
0.04
|
—
|
| Other Properties |
|
51.71
|
—
|
| Leases |
|
—
|
0.06
|
| Other Non Current Assets |
|
4.80
|
—
|
| Total Liabilities Net Minority Interest |
|
46.23
|
—
|
| Current Liabilities |
|
18.61
|
—
|
| Payables And Accrued Expenses |
|
8.19
|
—
|
| Payables |
|
1.50
|
—
|
| Accounts Payable |
|
1.50
|
—
|
| Current Accrued Expenses |
|
6.68
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
5.85
|
—
|
| Current Debt And Capital Lease Obligation |
|
4.21
|
—
|
| Current Capital Lease Obligation |
|
4.21
|
—
|
| Other Current Liabilities |
|
0.36
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
27.61
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
27.61
|
—
|
| Long Term Capital Lease Obligation |
|
27.61
|
—
|
| Stockholders Equity |
|
96.66
|
—
|
| Common Stock Equity |
|
96.66
|
—
|
| Capital Stock |
|
0.01
|
—
|
| Common Stock |
|
0.01
|
—
|
| Preferred Stock |
|
0.00
|
—
|
| Share Issued |
|
6.24
|
—
|
| Ordinary Shares Number |
|
6.24
|
—
|
| Treasury Shares Number |
|
0.00
-100.00%
|
0.01
|
| Additional Paid In Capital |
|
553.62
|
—
|
| Retained Earnings |
|
-456.99
|
—
|
| Gains Losses Not Affecting Retained Earnings |
|
0.02
|
—
|
| Other Equity Adjustments |
|
0.02
|
—
|
| Total Equity Gross Minority Interest |
|
96.66
|
—
|
| Total Capitalization |
|
96.66
|
—
|
| Working Capital |
|
77.89
|
—
|
| Invested Capital |
|
96.66
|
—
|
| Total Debt |
|
31.83
|
—
|
| Capital Lease Obligations |
|
31.83
|
—
|
| Net Tangible Assets |
|
96.66
|
—
|
| Tangible Book Value |
|
96.66
|
—
|
| Derivative Product Liabilities |
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-142.71
-43.20%
|
-99.66
+0.63%
|
-100.29
-17.79%
|
-85.14
|
| Cash Flow From Continuing Operating Activities |
|
-142.71
-43.20%
|
-99.66
+0.63%
|
-100.29
-17.79%
|
-85.14
|
| Net Income From Continuing Operations |
|
-695.98
-495.29%
|
-116.91
+0.81%
|
-117.86
-27.98%
|
-92.09
|
| Depreciation Amortization Depletion |
|
2.89
-18.17%
|
3.53
+1.03%
|
3.49
+38.30%
|
2.52
|
| Depreciation |
|
2.89
-18.17%
|
3.53
+1.03%
|
3.49
+38.30%
|
2.52
|
| Depreciation And Amortization |
|
2.89
-18.17%
|
3.53
+1.03%
|
3.49
+38.30%
|
2.52
|
| Other Non Cash Items |
|
518.02
+10176.23%
|
5.04
+6.64%
|
4.73
+32.11%
|
3.58
|
| Stock Based Compensation |
|
18.91
+92.06%
|
9.85
-26.31%
|
13.36
+24.94%
|
10.70
|
| Operating Gains Losses |
|
3.30
+18450.00%
|
-0.02
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
3.30
+18450.00%
|
-0.02
|
0.00
|
—
|
| Change In Working Capital |
|
10.21
+204060.00%
|
0.01
-99.23%
|
0.65
+106.61%
|
-9.84
|
| Change In Prepaid Assets |
|
1.68
+301.68%
|
-0.83
-125.54%
|
3.27
+1353.33%
|
0.23
|
| Change In Payables And Accrued Expense |
|
10.93
+387.73%
|
2.24
-21.37%
|
2.85
+155.83%
|
1.11
|
| Change In Other Current Assets |
|
0.00
-100.00%
|
2.43
+228.72%
|
-1.89
-161.72%
|
-0.72
|
| Change In Other Current Liabilities |
|
-2.41
+37.18%
|
-3.83
-6.89%
|
-3.58
+65.73%
|
-10.45
|
| Investing Cash Flow |
|
-48.80
-150.39%
|
96.86
+36.40%
|
71.01
+175.47%
|
-94.09
|
| Cash Flow From Continuing Investing Activities |
|
-48.80
-150.39%
|
96.86
+36.40%
|
71.01
+175.47%
|
-94.09
|
| Net PPE Purchase And Sale |
|
-0.14
+37.99%
|
-0.23
+78.58%
|
-1.07
+87.37%
|
-8.46
|
| Purchase Of PPE |
|
-0.94
-310.92%
|
-0.23
+78.58%
|
-1.07
+87.37%
|
-8.46
|
| Sale Of PPE |
|
0.80
|
0.00
|
—
|
—
|
| Capital Expenditure |
|
-0.94
-310.92%
|
-0.23
+78.58%
|
-1.07
+87.37%
|
-8.46
|
| Net Investment Purchase And Sale |
|
-48.66
-150.12%
|
97.09
+34.70%
|
72.08
+184.17%
|
-85.63
|
| Purchase Of Investment |
|
-53.66
-441.25%
|
-9.91
+86.77%
|
-74.92
+39.18%
|
-123.19
|
| Sale Of Investment |
|
5.00
-95.33%
|
107.00
-27.21%
|
147.00
+291.37%
|
37.56
|
| Financing Cash Flow |
|
503.81
+843.60%
|
53.39
+1717.29%
|
2.94
-97.49%
|
117.14
|
| Cash Flow From Continuing Financing Activities |
|
503.81
+843.60%
|
53.39
+1717.29%
|
2.94
-97.49%
|
117.14
|
| Net Common Stock Issuance |
|
328.21
+487.92%
|
55.83
+1119.42%
|
4.58
-96.05%
|
115.97
|
| Proceeds From Stock Option Exercised |
|
176.93
+163920.37%
|
-0.11
+88.30%
|
-0.92
-179.23%
|
1.17
|
| Net Other Financing Charges |
|
-1.32
+43.01%
|
-2.33
-224.27%
|
-0.72
|
—
|
| Changes In Cash |
|
312.29
+517.31%
|
50.59
+292.02%
|
-26.35
+57.57%
|
-62.09
|
| Beginning Cash Position |
|
84.36
+149.79%
|
33.77
-43.82%
|
60.12
-50.81%
|
122.21
|
| End Cash Position |
|
396.65
+370.18%
|
84.36
+149.79%
|
33.77
-43.82%
|
60.12
|
| Free Cash Flow |
|
-143.65
-43.81%
|
-99.89
+1.45%
|
-101.36
-8.28%
|
-93.61
|
| Amortization Of Securities |
|
-0.07
+94.17%
|
-1.15
+75.34%
|
-4.66
-38733.33%
|
-0.01
|
| Common Stock Issuance |
|
328.21
+487.92%
|
55.83
+1119.42%
|
4.58
-96.05%
|
115.97
|
| Issuance Of Capital Stock |
|
328.21
+487.92%
|
55.83
+1119.42%
|
4.58
-96.05%
|
115.97
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-13 View
- 42026-04-24 View
- 42026-04-21 View
- 42026-04-15 View
- 42026-04-10 View
- 42026-04-06 View
- 10-K2026-03-30 View
- 8-K2026-03-27 View
- 8-K2026-01-12 View
- 8-K2026-01-02 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 8-K2025-12-18 View
- 42025-12-09 View
- 42025-12-09 View
- 42025-12-09 View
- 8-K2025-12-09 View
- 10-Q2025-11-13 View
- 8-K2025-11-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|